OGA and cholangiocarcinoma: As PUGNAc, an inhibitor of OGA was used to enrich the O‐GlcNAcylation in CCA cells, we first determined whether PUGNAc treatment could increase O‐GlcNAcylation and enhance progression of CCA cells.